Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction.


Journal

Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765

Informations de publication

Date de publication:
02 01 2022
Historique:
received: 23 11 2021
revised: 24 12 2021
accepted: 29 12 2021
entrez: 20 1 2022
pubmed: 21 1 2022
medline: 26 2 2022
Statut: epublish

Résumé

This study aimed to investigate improvement in voiding condition after the initial botulinum toxin A (BoNT-A) injection into the urethral sphincter among patients with chronic spinal cord injury (SCI) and voiding dysfunction. Moreover, subsequent surgical procedures and bladder management were evaluated. From 2011 to 2020, 118 patients with SCI and dysuria who wanted to void spontaneously received their first BoNT-A injection at a dose of 100 U into the urethral sphincter. Improvement in voiding and bladder conditions after BoNT-A treatment were assessed. Next, patients were encouraged to continually receive BoNT-A injections into the urethral sphincter, convert to other bladder managements, or undergo surgery. After undergoing bladder management and surgical procedures, the patients were requested to report improvement in voiding condition and overall satisfaction to bladder conditions. Then, data were compared. In total, 94 male and 24 female participants were included in this analysis. Among them, 51 presented with cervical, 43 with thoracic, and 24 with lumbosacral SCI. After BoNT-A injections into the urethral sphincter, 71 (60.2%) patients, including 18 (15.3%) with excellent, and 53 (44.9%) with moderate improvement, had significant improvement in voiding condition. Patients with cervical SCI (66.6%), detrusor overactivity and detrusor sphincter dyssynergia (72.0%), partial hand function (80.0%), and incomplete SCI (68.4%) had a better improvement rate than the other subgroups. Only 42 (35.6%) patients continually received treatment with BoNT-A injections into the urethral sphincter. Meanwhile, more than 60% of patients who converted their treatment to augmentation enterocystoplasty ( Although BoNT-A injections into the urethral sphincter could improve voiding condition, only patients with SCI who presented with voiding dysfunction were commonly satisfied. Those whose treatments were converted to other bladder managements, which can promote urinary continence, or to surgical procedures, which can facilitate spontaneous voiding, had favorable treatment outcomes.

Identifiants

pubmed: 35051007
pii: toxins14010030
doi: 10.3390/toxins14010030
pmc: PMC8777981
pii:
doi:

Substances chimiques

Botulinum Toxins, Type A EC 3.4.24.69

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Schweiz Med Wochenschr. 2000 Oct 28;130(43):1618-26
pubmed: 11100516
Low Urin Tract Symptoms. 2019 Jan;11(1):66-71
pubmed: 29024564
Eur Urol. 2002 Jul;42(1):56-62
pubmed: 12121731
Urology. 2005 Jan;65(1):37-41
pubmed: 15667859
Eur J Phys Rehabil Med. 2011 Dec;47(4):639-50
pubmed: 22081065
J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1670-6
pubmed: 16291892
J Urol. 2003 Nov;170(5):1908-12
pubmed: 14532805
Urology. 2007 Oct;70(4):763-6
pubmed: 17707894
Spinal Cord. 2016 Jun;54(6):452-6
pubmed: 26712037
Eur Urol. 2005 Dec;48(6):984-90; discussion 990
pubmed: 16126328
Neurourol Urodyn. 2002;21(2):167-78
pubmed: 11857671
Nat Clin Pract Urol. 2006 Jul;3(7):368-80
pubmed: 16835625
J Urol. 1996 Mar;155(3):1023-9
pubmed: 8583552
J Rehabil Med. 2008 Oct;40(9):744-8
pubmed: 18843427
J Urol. 2019 Sep;202(3):574-584
pubmed: 30958741
Urology. 2000 Oct 1;56(4):565-8
pubmed: 11018603
Neurourol Urodyn. 2008;27(8):793-6
pubmed: 18508331
J Urol. 1988 May;139(5):919-22
pubmed: 3361663
Eur Urol. 2003 Aug;44(2):165-74
pubmed: 12875934
J Urol. 2007 Mar;177(3):1026-9
pubmed: 17296404
Arch Phys Med Rehabil. 2012 Apr;93(4):597-603
pubmed: 22365478
J Urol. 2001 Apr;165(4):1107-10
pubmed: 11257648
Arch Phys Med Rehabil. 1990 Jan;71(1):24-6
pubmed: 2297305
Can J Urol. 2011 Aug;18(4):5787-95
pubmed: 21854710
Urol Int. 2004;73(2):156-61; discussion 161-2
pubmed: 15331901
World J Urol. 2018 Oct;36(10):1517-1527
pubmed: 29752515
Int J Clin Pract. 2013 Oct;67(10):1044-9
pubmed: 24073977

Auteurs

Cheng-Ling Lee (CL)

Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan.

Jia-Fong Jhang (JF)

Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan.

Yuan-Hong Jiang (YH)

Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan.

Hann-Chorng Kuo (HC)

Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien 970, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH